MA58653B1 - Utilisation d'un dérivé de glutarimide pour traiter des maladies liées à l'activité aberrante d'interleukine-6 - Google Patents
Utilisation d'un dérivé de glutarimide pour traiter des maladies liées à l'activité aberrante d'interleukine-6Info
- Publication number
- MA58653B1 MA58653B1 MA58653A MA58653A MA58653B1 MA 58653 B1 MA58653 B1 MA 58653B1 MA 58653 A MA58653 A MA 58653A MA 58653 A MA58653 A MA 58653A MA 58653 B1 MA58653 B1 MA 58653B1
- Authority
- MA
- Morocco
- Prior art keywords
- activity
- aberrant
- interleukin
- diseases related
- treat diseases
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 102000004889 Interleukin-6 Human genes 0.000 title abstract 3
- 108090001005 Interleukin-6 Proteins 0.000 title abstract 3
- 230000001594 aberrant effect Effects 0.000 title abstract 3
- 230000000694 effects Effects 0.000 title abstract 3
- 229940100601 interleukin-6 Drugs 0.000 title abstract 3
- KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical class O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 title abstract 2
- 206010052015 cytokine release syndrome Diseases 0.000 abstract 3
- 208000025721 COVID-19 Diseases 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 230000035939 shock Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La présente invention se rapporte au domaine de la médecine et concerne un traitement de maladies associées à une activité aberrante l'interleukine-6 et au développement du syndrome de libération de cytokines (choc cytokinique), de préférence un traitement du covid-19, ainsi que d'autres maladies compliquées par une activité aberrante d'interleukine-6 et le développement d'un syndrome de libération de cytokines, ceci en utilisant un composé de 1-(2-(1-méthyl-1?-imidazol-4- yl)éthyl)pipéridine-2,6-dione (i). L'invention permet de créer un nouvel agent médicamenteux efficace pour le traitement de maladies associées au développement du syndrome de libération de cytokines.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2020121363A RU2774928C2 (ru) | 2020-06-26 | Применение производного глутаримида для терапии заболеваний, ассоциированных с аберрантной активностью интерлейкина-6 | |
| PCT/RU2021/050170 WO2021262040A1 (fr) | 2020-06-26 | 2021-06-18 | Utilisation d'un dérivé de glutarimide pour traiter des maladies liées à l'activité aberrante d'interleukine-6 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA58653A1 MA58653A1 (fr) | 2023-07-31 |
| MA58653B1 true MA58653B1 (fr) | 2024-02-29 |
Family
ID=79281595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA58653A MA58653B1 (fr) | 2020-06-26 | 2021-06-18 | Utilisation d'un dérivé de glutarimide pour traiter des maladies liées à l'activité aberrante d'interleukine-6 |
Country Status (7)
| Country | Link |
|---|---|
| CN (1) | CN115803026A (fr) |
| BR (1) | BR112022026356A2 (fr) |
| CL (1) | CL2022003725A1 (fr) |
| CO (1) | CO2023000604A2 (fr) |
| MA (1) | MA58653B1 (fr) |
| TN (1) | TN2022000350A1 (fr) |
| WO (1) | WO2021262040A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023177329A1 (fr) * | 2022-03-18 | 2023-09-21 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Utilisation de 1-(2-(1н-imidazol-4-yl)éthyl)pipéridine-2,6-dione pour le traitement de la toux induite par des infections virales |
| WO2023249516A1 (fr) * | 2022-06-24 | 2023-12-28 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Nouvelle forme cristalline de 1-[2-(1-méthylimidazol-4-yl)éthyl]perhydroazine-2,6-dione et utilisation pharmaceutique de celle-ci |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2112716A1 (de) * | 1971-03-17 | 1972-10-05 | Thomae Gmbh Dr K | Neue 4-(4-Biphenylyl)-4-oxobuttersaeuren,ihre Salze und ihre Ester |
| DE10002509A1 (de) * | 2000-01-21 | 2001-07-26 | Gruenenthal Gmbh | Substituierte Glutarimide |
| UA115431C2 (uk) * | 2011-10-11 | 2017-11-10 | Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" | Застосування глутарилгістаміну для лікування захворювань дихальних шляхів |
| CN102432544B (zh) * | 2011-11-17 | 2014-05-21 | 天津医科大学 | 5-取代苄亚甲基咪唑烷-2,4-二酮类衍生物及其应用 |
| EP3725785B1 (fr) * | 2013-04-12 | 2024-04-10 | Nebolsin, Vladimir | Dérivé de glutarimide, son utilisation, composition pharmaceutique basée sur celui-ci et procédés de production du dérivé de glutarimide |
| RU2552929C1 (ru) * | 2013-11-14 | 2015-06-10 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний |
| US10739353B2 (en) * | 2014-12-31 | 2020-08-11 | Signpath Pharma, Inc. | Suppression of cytokine release and cytokine storm |
| GEP20227402B (en) * | 2017-09-07 | 2022-08-10 | Valenta Intellekt Ltd | Use of glutarimide derivative to treat diseases related to aberrant activity of cytokines |
| MX2022012812A (es) * | 2020-04-13 | 2023-01-30 | Univ Health Network | Métodos para tratar el síndrome de liberación de citocinas. |
| CN113582980B (zh) * | 2020-04-30 | 2023-11-24 | 上海科技大学 | 基于杂环和戊二酰亚胺骨架的化合物及其应用 |
-
2021
- 2021-06-18 MA MA58653A patent/MA58653B1/fr unknown
- 2021-06-18 BR BR112022026356A patent/BR112022026356A2/pt not_active Application Discontinuation
- 2021-06-18 TN TNP/2022/000350A patent/TN2022000350A1/en unknown
- 2021-06-18 CN CN202180044905.7A patent/CN115803026A/zh active Pending
- 2021-06-18 WO PCT/RU2021/050170 patent/WO2021262040A1/fr not_active Ceased
-
2022
- 2022-12-22 CL CL2022003725A patent/CL2022003725A1/es unknown
-
2023
- 2023-01-19 CO CONC2023/0000604A patent/CO2023000604A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2022003725A1 (es) | 2023-05-19 |
| WO2021262040A1 (fr) | 2021-12-30 |
| CN115803026A (zh) | 2023-03-14 |
| BR112022026356A2 (pt) | 2023-01-17 |
| RU2020121363A3 (fr) | 2021-12-27 |
| MA58653A1 (fr) | 2023-07-31 |
| RU2020121363A (ru) | 2021-12-27 |
| TN2022000350A1 (en) | 2024-07-04 |
| CO2023000604A2 (es) | 2023-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Matalon et al. | Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir | |
| MA57972B1 (fr) | Inhibiteurs de parp1 | |
| MA65131B1 (fr) | Utilisation d'un inhibiteur d'ezh2 dans la préparation d'un médicament pour le traitement d'un lymphome à cellules t | |
| MA57412B1 (fr) | Benzopyrrole substitués et inhibiteurs du complément structurellement apparentés | |
| EA202090955A1 (ru) | Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови | |
| MA58653A1 (fr) | Utilisation d'un dérivé de glutarimide pour traiter des maladies liées à l'activité aberrante d'interleukine-6 | |
| MA53399B1 (fr) | Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine | |
| MA33053B1 (fr) | Inhibiteurs de la poly(adp-ribose) polymerase (parp) | |
| NO20025601D0 (no) | Arylmetylaminderivater for anvendelse som tryptaseinhibitorer | |
| EP2329842A3 (fr) | Inhibiteurs d'interleukine 1 dans le traitement de maladies | |
| MA40814A1 (fr) | Compositions pharmaceutiques pour thérapie combinée | |
| TNSN07063A1 (fr) | Utilisations therapeutiques d'inhibiteurs de rtp801 | |
| HRP20050533A2 (en) | Aminoindazole derivatives and use thereof as kinase inhibitors | |
| EA200200591A1 (ru) | ПИРРОЛИДИНЫ, КОТОРЫЕ ИНГИБИРУЮТ цАМФ-СПЕЦИФИЧНУЮ PDE | |
| CR7882A (es) | Compuestos 2-(1H-Indazol-6-ilamino-benzamidas como inhibidores proteinquinasas utiles para el tratamiento de enfermedades oftalmicas | |
| CL2004000366A1 (es) | USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA. | |
| MY172303A (en) | Compositions and methods of use of phorbol esters | |
| EA200201276A1 (ru) | Производные арилметиламина для использования в качестве ингибиторов триптазы | |
| MA43052B1 (fr) | Inhibiteurs de la kallicréine plasmatique humaine | |
| Machado Andrade et al. | Host and viral factors influencing interplay between the macrophage and HIV-1 | |
| CA3156269A1 (fr) | Inhibiteurs de facteur d du complement oral | |
| NO20052272L (no) | CCR1-antagonister for behandling av blant annet demylinerene inflamasjonssykdom | |
| MA53010B1 (fr) | Formulations d'un inhibiteur de axl/mer | |
| MX2025008009A (es) | Moduladores de la proteolisis de bcl6 y metodos de uso asociados | |
| MA53372B1 (fr) | Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine |